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Abstract
Background: Optimal antimicrobial drug exposure in the lung is required for successful treatment outcomes for
nosocomial pneumonia. Little is known about the intrapulmonary pharmacokinetics (PK) of meropenem when
administered by continuous infusion (CI). The aim of this study was to evaluate the PK of two dosages of
meropenem (3 g vs 6 g/day by CI) in the plasma and epithelial lining fluid (ELF) in critically ill patients with
nosocomial pneumonia.
Methods: Thirty-one patients (81% male, median (IQR) age 72 (22) years) were enrolled in a prospective,
randomized, clinical trial. Sixteen patients received 1 g/8 h and 15 2 g/8 h by CI (8 h infusion). Plasma and ELF
meropenem concentrations were modeled using a population methodology, and Monte Carlo simulations were
performed to estimate the probability of attaining (PTA) a free ELF concentration of 50% of time above MIC
(50% fT>MIC), which results in logarithmic killing and the suppression of resistance in experimental models of
pneumonia.
Results: The median (IQR) of meropenem AUC0–24 h in the plasma and ELF was 287.6 (190.2) and 84.1 (78.8) mg h/
L in the 1 g/8 h group vs 448.1 (231.8) and 163.0 (201.8) mg h/L in the 2 g/8 h group, respectively. The penetration
ratio was approximately 30% and was comparable between the dosage groups. In the Monte Carlo simulations,
only the highest approved dose of meropenem of 2 g/8 h by CI allowed to achieve an optimal PTA for all isolates
with a MIC < 4 mg/L.
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Conclusions: An increase in the dose of meropenem administered by CI achieved a higher exposure in the plasma
and ELF. The use of the highest licensed dose of 6 g/day may be necessary to achieve an optimal coverage in ELF
for all susceptible isolates (MIC ≤ 2 mg/L) in patients with conserved renal function. An alternative therapy should
be considered when the presence of microorganisms with a MIC greater than 2 mg/L is suspected.
Trial registration: The trial was registered in the European Union Drug Regulating Authorities Clinical Trials
Database (EudraCT-no. 2016-002796-10). Registered on 27 December 2016.
Keywords: Meropenem, Population pharmacokinetics, Pharmacodynamics, Critically ill patients, Nosocomial
pneumonia, Lung penetration, Dose selection
Key points
This is the first article assessing the lung penetration of
different doses of meropenem administered by continu-
ous infusion in critically ill patients with nosocomial
pneumonia. A dose increase leads to higher plasma and
epithelial lining fluid concentrations allowing to achieve
an optimal probability of target attainment for all
susceptible microorganisms.
Background
The relatively high incidence, rising rates of antimicro-
bial resistance, and suboptimal clinical outcomes of pa-
tients with nosocomial pneumonia provide the impetus
to optimize the use of existing antibiotics [1–4].
Meropenem is a carbapenem antibiotic with potent ac-
tivity against many of the pathogens that cause nosoco-
mial pneumonia [1]. It exhibits time-dependent
pharmacodynamics (PD); the fraction of the dosing
interval that free plasma concentrations are above the
MIC (fT>MIC) is the PK/PD index that best describes
its antimicrobial efficacy [2, 3]. Although the maximal
bactericidal activity for meropenem has been associated
with a fT>MIC of 40–50% [4], a higher pharmacody-
namic target of 50–100% fT>MIC has been suggested
for critically ill patients [5]. Continuous (CI) (or ex-
tended) infusion of β-lactam antibiotics increases the
fT>MIC and has been linked to improved clinical out-
comes in some clinical studies [6–8]. The emergence of
resistance is another important endpoint, so regimens
must be designed to provide drug exposures that
minimize the development of resistance [9, 10].
Plasma drug exposures are frequently used as a proxy
for effect-site concentrations. However, in some cases,
they may be misleading, and measurement of antimicro-
bial concentrations at the site of infection might be more
relevant for predicting clinical response [11]. The epithe-
lial lining fluid (ELF) is the most clinically relevant com-
partment to estimate intrapulmonary drug concentrations
[12, 13]. In a murine pneumonia model for meropenem, a
fT>MIC of 50% in ELF has been associated with logarith-
mic bacterial killing and suppression of resistant subpopu-
lation amplification [14].
In this study, we investigated the utility of CI to
achieve drug exposures in the human lung which are
predicted to be effective and suppress the emergence of
resistance. Specifically, we sought to (1) estimate plasma
and ELF concentrations of meropenem in critically ill
patients with nosocomial pneumonia receiving 3–6 g/
day by CI, (2) describe the population pharmacokinetics
(popPK) of meropenem in this population, and (3) esti-
mate regimens that achieve effective drug exposures in
ELF against Gram-negative pathogens with MIC likely
to be encountered in patients with pneumonia.
Methods
Study design, settings, and patients
This was a single-center, prospective, open-label, ran-
domized, comparative PK clinical trial that was con-
ducted at a tertiary surgical intensive care unit (ICU) at
the Parc de Salut Mar in Barcelona, Spain, between
January 2017 and February 2019. The study was
approved by the local ethics committee (Comitè Etic
d’Investigació Clínica del Parc de Salut Mar; approval
no. 2016/7125) and the Spanish Medicines and Health
Product Agency (AEMPS; registration no. 16-0774). Fur-
thermore, the trial was registered in the European Union
Drug Regulating Authorities Clinical Trials Database
(EudraCT-no. 2016-002796-10). Written informed con-
sent was obtained from the patients or their legal
representatives.
The inclusion criteria were as follows: age ≥ 18 years,
diagnosis of nosocomial pneumonia and risk factors for
multidrug-resistant (MDR) pathogens [Pseudomonas aer-
uginosa, Acinetobacter spp., and extended-spectrum β-
lactamases (ESBL)-producing Gram-negative Bacilli] [15],
and glomerular filtration rate (GFR) ≥ 50mL/min/1.73 m2
(estimated using the Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) formula [16]). The exclu-
sion criteria were allergy to β-lactams, previous use of
carbapenems within 15 days, GFR < 50mL/min/1.73 m2,
severely impaired liver function [cirrhosis grade C by
Child-Pugh classification [17]], obesity (body mass index
(BMI) > 30), pregnancy, life expectancy < 3 days, and
colonization [respiratory secretions or surveillance
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cultures (oropharyngeal and rectal swabs)] with pathogens
known to be resistant to meropenem.
The diagnosis of pneumonia was based on standard
clinical and laboratory criteria and defined as a new or
progressive radiological pulmonary infiltrate plus two or
more of the following characteristics: temperature >
38 °C or < 35 °C, leucocyte count > 11,000 or < 4000
cells/mm3, or purulent respiratory secretions [15].
Data collection
The following data were collected at the onset of treat-
ment: demographics, BMI, Charlson Comorbidity Index
[18], Acute Physiology and Chronic Health Evaluation II
(APACHE) score [19] and SOFA score, type of pneumo-
nia [hospital-acquired (HAP) or ventilator-associated
(VAP)], sepsis or septic shock [20], presence of fluid
overload, and mechanical ventilation. HAP was defined
as pneumonia not incubating at the time of hospital ad-
mission and occurring ≥ 48 h after admission. VAP was
defined as pneumonia occurring > 48 h after endo-
tracheal intubation [15]. Laboratory data such as renal
function (GFR and serum urea at baseline and on day 3),
biomarkers [C-reactive protein (CRP), pro-calcitonin
(PCT)], serum albumin, and total serum proteins were
collected.
Clinical cure at the end of treatment, length of ICU
and hospital stay (LOS), 7- and 30-day all-cause mortal-
ity, in-hospital mortality, and microbiological data (iso-
lated organism, MIC value, and microbiological
eradication) were recorded. Clinical cure was defined as
the resolution of signs and symptoms present at enrol-
ment and the resolution or lack of progression of radio-
logical signs of pneumonia during follow-up (7 to 10
days after treatment initiation) [21]. Microbiological
eradication was defined as the eradication of the micro-
organisms cultured from respiratory samples at baseline
and at the end of treatment [22]. Seven and 30-day all-
cause mortality was considered as death from any cause
during the 7 or 30 days following the end of treatment,
and in-hospital mortality was defined as death occurring
during the hospital stay. Antibiotic susceptibility testing
of the isolated pathogens was determined using the
Vitek2® automated system (Biomerieux, France) and
interpreted according to EUCAST breakpoints (Euro-
pean Committee on Antimicrobial Susceptibility Test-
ing) [23]. In a few cases, susceptibility was confirmed by
E-test (Biomerieux, France). Adverse events potentially
associated with meropenem were collected such as local
(inflammation, pain, phlebitis or edema at the injection
site), cutaneous (rash, pruritus), gastrointestinal (diar-
rhea, nausea/vomiting, constipation), neurological (head-
ache, insomnia, agitation, delirium, confusion, dizziness,
seizure, nervousness, paresthesia, hallucinations, somno-
lence), drug-induced liver injury (increased alanine
aminotransferase, aspartate aminotransferase, alkaline
phosphatase, lactate dehydrogenase, bilirubin), or Clos-
tridioides difficile-associated diarrhea (CDAD).
Randomization
Based on previous PK-related studies [24, 25], an initial
sample size of 30 patients was considered for the desired
level of significance. All included patients were random-
ized to receive 3 g or 6 g of i.v meropenem per day.
Randomization was performed by an individual not re-
lated to the study using the SISA computer program
(simple interactive statistical analysis). Randomization
was balanced (1:1) without blocks or stratification. All
patients received meropenem (Meropenem Accord-
pharma®; Accord Healthcare, S.L.U. Barcelona, Spain) at
an initial loading dose (LD) of 2 g (in 50mL of 0.9% sa-
line infused by a central line in 15min) followed by a CI
of 3 g or 6 g/day (1 g or 2 g of meropenem over 8 h every
8 h). Meropenem by CI was diluted in 100 mL of 0.9%
saline solution and injected into a central venous cath-
eter via a volumetric pump (Braum Mesulgen, Mesulgen,
Germany) with an infusion dead space of < 2 mL [26]. A
maximum infusion time of 8 h was chosen based on the
available meropenem stability data [27] and a stability
study performed in our laboratory to confirm the previ-
ous results (data not shown). All patients received em-
pirical combination therapy with 3 MIU/8 h of nebulized
colistimethate sodium (CMS) (Accord®, Accord Health-
care, Barcelona, Spain). Nebulization was performed
using a vibrating-mesh nebulizer (Aeroneb Pro®, Aero-
gen, Galway, Ireland) as it was described in a previous
study [28].
Pharmacokinetic study
Blood and ELF samples were obtained after the third or
fourth day of treatment once a steady state had been
achieved. Blood samples were collected pre-infusion and
at 1.5, 3, 6, and 8 h after the start of meropenem infu-
sion. ELF samples were obtained simultaneously at 6 h
post-infusion by bronchoalveolar lavage (BAL) during a
standardized fiberoptic bronchoscopy using a broncho-
scopic BAL catheter procedure (Combicath®, Prodimed,
Le Plessis Bouchard, France) by instilling three aliquots
of sterile 0.9% saline (20 mL, 40 mL, and 40 mL). The
time between the beginning of BAL and the total recov-
ery of the three aliquots did not exceed 2min for each,
in order to minimize the free diffusion of urea through
the alveolar epithelium, which might lead to falsely
elevated concentrations of urea in the BAL fluid [29].
The liquid recovered from the first aliquot was rejected,
since it is not considered representative of ELF [30].
Blood and ELF samples were centrifuged at 4 °C, and the
supernatant was frozen at − 80 °C until analysis.
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Bioanalytical methods
Meropenem concentrations were measured using a vali-
dated high-performance liquid chromatography (HPLC)
method [31] at the Pharmacy Department of Hospital
del Mar. The assay was linear from 0.5 to 80mg/L and
0.03 to 1 mg/L in the plasma and BAL, respectively.
Precision and accuracy were ≤ 15% at high, medium, and
low concentrations. The limit of quantification was 0.5
and 0.03 mg/L in the plasma and BAL, respectively.
Normal serum saline (0.9%) was used to prepare the
standard calibrators of meropenem in BAL.
Concentrations of urea in the plasma and ELF were
determined with the Urea/BUN kit (Roche® professional
Diagnostics, Mannheim, Germany) being the LOQ 3
mg/dL in the plasma and 0.078 mg/dL in ELF.
Meropenem concentration in ELF (MERELF) was deter-
mined according to the following formula, using urea as an
endogenous marker, to correct the meropenem concentra-
tions in ELF following dilution from the BAL [32, 33]:
MERELF ¼ MERBAL  UreaSER=UREABAL
where MERBAL is the meropenem concentration mea-
sured in BAL, UreaSER is the urea concentration in the
plasma, and UreaBAL is the urea concentration in BAL.
Population pharmacokinetic model
Population pharmacokinetic modeling was performed
using the nonparametric adaptive grid (NPAG) approach
embedded in Pmetrics (Los Angeles, CA, USA) [34, 35].
One-, two-, and three-compartment structural models
were fitted to the data and evaluated. Elimination from
the central compartment and intercompartmental distri-
bution were modeled as first-order processes. Data were
weighted using the inverse of the estimated assay
variance, and additional process noise was modeled
using gamma as a multiplicative error term.
Age, gender, actual body weight (ABW), APACHE
score, serum creatinine, GFR, serum albumin, total
serum proteins, serum urea, CRP, PCT, presence of sep-
tic shock, presence of fluid overload, and mechanical
ventilation were evaluated as covariates using stepwise
linear regression. Potential covariates were separately
entered into the model and retained if their inclusion
resulted in a statistically significant improvement in the
log likelihood value and/or in the observed-predicted
plots.
The fit of each model to the data was assessed using a
linear regression of observed-predicted values both be-
fore and after the Bayesian step. The mean prediction
error and the mean bias-adjusted squared prediction
error were used to assess bias and imprecision,
respectively. Models were compared by calculating twice
the difference in the log likelihood values.
The final model was also evaluated graphically and sta-
tistically by visual predictive checks (VPCs) performed
from normalized prediction distribution errors (NPDEs)
[36]. One thousand datasets were simulated using the
final population model parameters. For the VPCs, the
5th, 50th, and 95th percentiles of the simulated concen-
trations were processed using the R platform, plotted
against elapsed time, and compared to observed concen-
trations. For a model in which random effects are well
estimated, approximately 90% of the observed data are
expected to be within the 5th to 95th prediction interval.
NPDE results were summarized graphically by default as
provided by the NPDE R package (version 1.2) using (i)
a Q-Q plot (where Q is quantile) of the NPDE and (ii) a
histogram of the NPDE.
Other pharmacokinetic calculations
The average AUC in the plasma and ELF for each pa-
tient was estimated using the Bayesian posterior para-
metric estimates from the final model using the
trapezoidal rule in Pmetrics. The daily average AUC
(AUC0–24) was calculated by dividing the cumulative
AUC of each patient by the total time in hours and
multiplying the obtained result by 24 h. The partitioning
of meropenem into ELF was described using the ratio of
AUC0–24 h ELF/AUC0–24 h plasma.
Monte Carlo simulations
Monte Carlo simulations (n = 1000) of plasma concen-
trations were employed to calculate the fT≥MIC in ELF
on the third day of treatment (from 48 to 72 h post-
treatment) Three different meropenem regimens (2 g of
LD followed by a maintenance dose of 1 g/8 h in CI, 2 g
of LD followed by a maintenance dose of 2 g/8 h in CI,
and 3 g of LD followed by a maintenance dose of 3 g/8 h
in CI) against a range of MIC values (0.002–16mg/L)
were examined. Human protein binding of 2% in the
plasma was used to estimate free drug concentrations in
the plasma [37] while measured total concentrations in
ELF were regarded as equivalent to the free fraction
because protein binding is expected to be negligible [38].
A probability of target attainment (PTA) ≥ 90% was con-
sidered optimal. The AUC48–72 h in the plasma and ELF
with two different dosages of meropenem were also
simulated.
The potential toxicity of the different regimens was
estimated by calculating the probability of achieving the
threshold meropenem concentrations in the plasma
associated with 50% risk of developing a neurotoxicity
event, which has been defined as a minimum concentra-
tion (Cmin) in the plasma ≥ 64.2 mg/L [39].
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Statistical analysis
Dichotomous variables were compared using the chi-
square test and Fisher’s exact test. Quantitative data
were expressed as medians [interquartile range
(IQR)] and compared using the Mann-Whitney U
test. Correlations were analyzed using Spearman’s
correlation. A P value of < 0.05 was considered
statistically significant. The SPSS (SPSS, Chicago, IL,
USA) version 24.0 statistical package was used
throughout.
Results
Enrolment and characteristics of study patients
Thirty-one patients were enrolled: 16 in the 1 g/8 h
group and 15 in the 2 g/8 h group. A subject in the 1 g/
8 h group was excluded due to problems with BAL sam-
ple processing. To compensate, an additional patient
was recruited and randomized (Fig. 1). The demographic
and clinical characteristics of both groups are summa-
rized in Table 1. Most patients were male (81%), with a
median (IQR) age of 72 (22) years and APACHE score
of 15 (8). No significant differences in any demographic
or clinical variable were observed between the two
groups except for a higher Charlson score in the 2 g/8 h
group.
In total, 25 pathogens (20 Gram-negative, 4 Gram-
positive, and 1 virus) were isolated in respiratory cul-
tures from 17 patients (9 in the 1 g/8 h group and 16 in
the 2 g/8 h group). In 14 (45%) patients, no pathogen
was isolated. Five patients had a polymicrobial infection.
All patients with Gram-positive and viral isolates were in
the 2 g/8 h group (2 methicillin-susceptible and 2
methicillin-resistant Staphylococcus aureus and 1 influ-
enza B virus).
More patients in the 2 g/8 h group had a positive cul-
ture in BAL fluid (10/15 (66.7%) compared to 5/16
(31.3%) in the 1 g/8 h group (P = 0.049). Five patients
had positive blood cultures with Gram-negative bacteria
being 3 in the 1 g/8 h group and 2 in the 2 g/8 h group
with no differences between the groups (P > 0.999). Only
those patients with Gram-negative isolates were included
in the PK/PD analysis. The Gram-negative isolates were
3 Haemophilus influenzae, 6 Enterobacteriaceae (2 sus-
ceptible Escherichia coli and 2 ESBL-E. coli, 1 Klebsiella
pneumoniae, and 1 ESBL-K. pneumoniae), and 5 P. aeru-
ginosa (2 multi-susceptible, 1 MDR, and 2 extensively
drug-resistant P. aeruginosa). Microbiological data and
distributions of MICs in the two groups are shown in
Table 1. All included patients initially received an empir-
ical combination therapy of intravenous meropenem
Fig. 1 Enrolment and follow-up of the study patients
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Table 1 Patient’s characteristics and clinical data comparing the two study groups
Characteristics 1 g/8 h group (N = 16) 2 g/8 h group (N = 15) P value
Demographic and clinical data
Male, n (%) 12 (75) 13 (86.7) 0.654
Age (years) 64.0 (20.0) 75.0 (14.0) 0.202
Body weight (kg) 74.0 (14.8) 70.0 (15.0) 0.495
BMI (kg/m2) 26.8 (3.8) 25.5 (6.4) 0.338
Charlson Comorbidity Index 4.0 (3.5) 6.0 (4.0) 0.033
APACHE II scorea 13.0 (10.8) 15.0 (6.0) 0.423
Other clinical datab
Type of pneumonia, n (%) > 0.999
Ventilator-associated pneumonia 4 (25) 4 (26.7)
Hospital-acquired pneumonia 12 (75) 11 (73.3)
SOFA score 5 (4) 5 (5) 0.830
Septic shock, n (%) 4 (25) 3 (20) > 0.999
Sepsis, n (%) 10 (62.5) 12 (80) 0.433
Concomitant bacteremia, n (%) 3 (18.8) 2 (13.3) > 0.999
Fluid overload, n (%) 2 (12.5) 6 (40) 0.113
Mechanical ventilation, n (%) 4 (25) 4 (26.7) > 0.999
GFR (mL/min/1.73 m2) 103.0 (33.0) 85.0 (30.0) 0.281
GFR < 90 mL/min/1.73 m2, n (%) 6 (37.5) 9 (60.0) 0.210
GFR > 120 mL/min/1.73 m2, n (%) 2 (12.5) 3 (13.3) > 0.999
C-reactive protein (mg/dL) 15.0 (26.9) 17.5 (14.1) 0.654
Procalcitonin (ng/mL) 0.8 (2.1) 0.9 (3.6) 0.375
Total serum protein (g/dL) 5.2 (1.4) 5.1 (1.0) 0.830
Serum albumin (g/dL) 2.9 (0.9) 2.8 (0.6) 0.599
Clinical and microbiological outcomes
Clinical cure, n (%) 13 (81.3) 11 (73.3) 0.685
Length of ICU stay (days) 19.9 (15.8) 18.2 (17.4) 0.730
Length of hospital stay (days) 39.5 (54.8) 28.0 (55.0) 0.682
Microbiological eradication, n (%) 4 (25.0%) 7 (46.7%) 0.494
Seven-day all-cause mortality, n (%) 0 (0) 0 (0) > 0.999
Thirty-day all-cause mortality, n (%) 1 (6.3) 1 (6.7) > 0.999
In-hospital mortality, n (%) 1 (6.3) 1 (6.7) > 0.999
Microbiological data: specie, n (%)/MIC (mg/L)c
Gram-negative bacteria 6 (37.5) 7 (46.7) 0.605
MDR Gram-negative bacteria 3 (18.8) 2 (13.3) > 0.999
Pseudomonas aeruginosa (PA) 3 (18.8) 2 (13.3) > 0.999
Multi-susceptible PA 2 (12.5)/≤ 2 0 (0) 0.484
MDR PA 0 (0) 1 (6.7)/16 0.484
XDR PA 1 (6.3)/8 1 (6.7)/32 > 0.999
Enterobacteriaceae 3 (18.8) 3 (20.0) > 0.999
ESBL producers 3 (18.8) / ≤2 0 (0) 0.226
Other Gram-negative bacteria 1 (6.3)/≤ 2 3 (20.0)/≤2 0.333
MDR multidrug-resistant, XDR extensively drug-resistant, ESBL extended-spectrum beta-lactamases
aCalculated at the beginning of ICU admission
bData at the onset of treatment
cBased on EUCAST breakpoints
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plus 3 MIU/8 h of nebulized colistimethate sodium due
to the high prevalence of MDR P. aeruginosa in our unit.
After having the results of the microbiological cultures,
meropenem was finally used empirically in 18 patients
(58%) and as targeted therapy in 13 (42%) patients. In
those cases with a MDR or XDR P. aeruginosa isolation,
the initial combination therapy of meropenem plus
nebulized CMS was maintained and monotherapy with
meropenem was used only when a more susceptible
Gram-negative bacteria were isolated. When a Gram-
negative bacterium resistant to meropenem was cultured
(2 patients in the 2 g/8 h group and 1 patient in the 1 g/8 h
group), escalation was done being ceftolozano-tazobactam
plus CMS the most frequent combination.
In seven patients clinical cure was not achieved
(three in the 1 g/8 h group and four in the 2 g/8 h
group), but only two of them died, one in each group.
In three patients, the initial treatment with merope-
nem was changed by ceftolozane-tazobactam with late
favorable clinical response (one in the 1 g/8 h group
and two in the 2 g/8 h group). In two patients, the
clinical cure was achieved after a long treatment of
meropenem plus nebulized CMS plus linezolid (one
of each group). Finally, the other two died, one in the
1 g/8 h group due to a stroke on the eighth day of
treatment with no documented clinical cure at that
point and the other in the high dose group due to
MRSA pneumonia.
No adverse events related to meropenem treatment
were observed in any patient. The BAL procedure was
well tolerated in all cases.
Pharmacokinetic data
The concentration-time profiles of meropenem in
the plasma and ELF in both groups are shown in
Fig. 2. Median (IQR) meropenem plasma concentra-
tions in the 2 g/8 h group were statistically higher at
all times points compared to the 1 g/8 h group. In
ELF, concentrations were also higher in the 2 g/8 h
group, but this difference did not reach statistical
significance (6.6 (8.3) mg/L vs 3.9 (3.2) mg/L), re-
spectively (P = 0.102). A high interindividual varia-
bility was observed in ELF exposure within both
groups.
Population pharmacokinetic model
A total of 151 meropenem plasma concentrations and
30 ELF concentrations were included in the population
analysis. A 3-compartment linear model, with zero-order
input and first-order clearance from the central com-
partment, best described the data. Concentrations of
meropenem in ELF were modeled by assuming ELF was
a homogenous compartment with volume, VELF. Com-
partments were connected by first-order intercompart-
mental rate constants.
Despite different covariates, such as BMI, serum
creatinine, and GFR, having a relationship with the
estimated clearance, they were not included in the final
model because they did not improve the goodness-of-fit.
Estimates for central tendency, dispersion, and 95%
credibility limits for the population PK parameters are
shown in Table 2.
The observed-predicted values for meropenem con-
centrations in the plasma and ELF before and after
the Bayesian step are shown in Fig. 3. After max-
imum a posteriori probability (MAP)-Bayesian estima-
tion, a linear regression of the observed-vs-predicted
values in the plasma had an intercept and slope of
0.0159 (CI95 − 0.685–0.717) and 1.02 (CI95 0.984–
1.05), respectively, and an R2 = 0.956. The bias and
Fig. 2 Meropenem plasma and ELF concentration-time profiles. Meropenem plasma and ELF concentration time profiles of patients receiving a
loading dose of 2000 mg i.v followed by a maintenance dose of 1 g q8h and 2 g q8h i.v. Intensive sampling was performed after the second day
of treatment. A statistically significant difference was observed in plasma concentrations at any time points between the two groups
(meropenem plasma concentrations of 12.9 (8.4) vs 23.0 (12.8) at pre-dose; 13.4 (7.3) vs 23.9 (16.7) at 1.5 h; 13.3 (8.3) vs 21.4 (15.5) at 3 h; 11.7 (8.2)
vs 22.4 (15.3) at 6 h, and 12.3 (9.1) vs 18.9 (17.4) at 8 h, in the 1 g/8 h and 2 g/8 h groups, respectively).
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imprecision were both acceptable (bias = − 0.0803mg/L
and imprecision 1.23mg/L). For ELF, the observed-vs-
predicted plot had an intercept and slope of − 0.0784
(CI95 − 0.211–0.0546) and 1.00 (CI95 0.988–1.02),
respectively, and an R2 = 0.999. The bias and imprecision
were both acceptable (bias = 0.114mg/liter and impreci-
sion 0.189mg/L).
Visual predictive check plots of the different doses
(1 g/8 h and 2 g/8 h) in the plasma and ELF based on
1000 simulations with the final model are given in
Fig. 7. The normal distribution of normalized predic-
tion distribution errors (NPDEs) in the plasma and
ELF confirmed the adequacy of the model for dosing
simulations. Median (IQR) average values of AUC0–24
in the plasma and ELF estimated using the Bayesian
posterior parametric estimates for each patient are
shown in Table 3. Both AUC0–24, in the plasma and
ELF, were statistically higher in the 2 g/8 h group than
in the 1 g/8 h group. The penetration ratio was similar
between the groups.
The AUC0–24 in ELF showed a moderate positive
linear correlation with AUC0–24 in the plasma, age, and
APACHE score (Spearman rho = 0.533, 0.575, and 0.537,
respectively) (P < 0.05) and an inverse correlation with
patients’ ABW, BMI, and GFR (Spearman rho = − 0.688,
− 0.598, and − 0.376, P < 0.05). Figure 4 shows the com-
parison between the individual predicted AUC48–72 h
using the Bayesian posteriors (red diamonds) and the
simulated AUC48–72 h (black diamonds) in the plasma
and ELF with two different dosages of meropenem.
Table 2 Population pharmacokinetic parameters of meropenem
Parameter (units) Median Mean 95% credibility limits Standard deviation
CL (L/h) 11.219 12.464 8.539–15.589 5.570
V (L) 10.143 12.500 8.385–17.194 6.929
K12 (h
−1) 26.696 22.987 23.706–27.897 8.072
K21 (h
−1) 7.601 11.721 3.853–21.014 9.730
K13 (h
−1) 18.539 17.317 13.124–21.815 5.611
K31 (h
−1) 25.614 24.451 23.575–28.602 5.892
VELF (L) 19.424 25.319 19.321–28.525 10.735
CL clearance; V volume of the central compartment; K12, K21, K13, and K31 first-order intercompartmental rate constants; VELF volume of the ELF compartment
Fig. 3 Population and individual predicted meropenem concentrations vs observed meropenem concentrations in the plasma and in ELF.
Population (a) and individual (b) predicted meropenem concentrations vs observed concentrations of meropenem in the plasma (a and b,
respectively) and in ELF (c and d, respectively). The broken line is the line of identity (observed = predicted concentrations)
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Probability of target attainment
The probability of target attainment (PTA) for achieving
50% fT>MIC in ELF for the three different meropenem
doses on day 3 of treatment is shown in Fig. 5. With the
lowest dose (2 g LD+ 1 g/8 h by CI), an optimal PTA could
be achieved for isolates with MICs of < 2mg/L. With the
administration of a double maintenance dose (2 g LD + 2 g/
8 h), a PTA ≥ 90% in ELF could be attained for isolates with
MIC up to 2mg/L, which is the current susceptibility
breakpoint [23]. A dosage increases to 3 g LD+ 3 g/8 h by
CI did not result in significantly greater coverage of MIC.
We also estimated the dose needed for isolates with inter-
mediate susceptibility (MIC between 2 and ≤ 8mg/L) that
was estimated to be as high as 8 g/8 h, which is four times
higher than the maximum licensed meropenem dose.
Figure 6 shows the simulated meropenem concentration-
time profiles in ELF of each tested regimen.
Similar results were obtained with the administration
of meropenem in an extended infusion of 4 h. The prob-
ability of target attainment (PTA) for achieving 50%
fT>MIC in ELF was also assessed on day 3 of treatment
for three different meropenem doses (1 g/8 h, 2 g/8 h,
and 3 g/8 h) administered by extended infusion (4 h)
(Fig. 7). With the lowest dose of 1 g/8 h, an optimal PTA
could be achieved for isolates with MICs of < 2 mg/L,
and with higher doses (2 g/8 h and 3 g/8 h), the coverage
increased to a MIC up to 2 mg/L.
From the point of view of toxicity, the probability of
achieving a Cmin in the plasma of meropenem ≥ 64.2mg/L
during the first 3 days of treatment was estimated to be
0% for the two lowest doses and 1.7% for the 3 g/8 h dose.
In comparison, the use of the highest dose (8 g/8 h)
resulted in nearly half of the patients (49.0%) achieving
this potentially toxic trough concentration.
PK/PD in ELF and clinical outcomes
Twelve patients with documented Gram-negative bacter-
ial infections were eligible for the PK-PD sub-study.
All patients that achieved clinical cure had a fT>MIC
> 50% in ELF in both groups, compared to patients who
failed treatment (fT>MIC 33.3%, P = 0.045). Regarding
the microbiological results, a higher proportion of
patients with eradication achieved an optimal ELF target,
but this difference was not statistically significant (88.9%
vs 66.7%, P = 0.455). No correlation was found between
the duration of mechanical ventilation (days) and mero-
penem ELF or plasma meropenem concentrations (data
not shown).
Discussion
Meropenem is a licensed agent for the treatment of
nosocomial pneumonia [15]. As for other β-lactams, the
pharmacodynamics of meropenem is optimized with the
use of prolonged infusions, especially CI [6–8]. In recent
years, higher meropenem dosages are being recom-
mended to avoid suboptimal exposure [40], but the
clinical benefits are still unknown.
Table 3 Median (IQR) average AUC48–72 h in the plasma and ELF in the two dose groups estimated using the Bayesian posterior
parametric estimates for each patient
1 g/8 h group (N = 16) 2 g/8 h group (N = 15) P
AUC0–24 in the plasma (mg h/L) 322.7 (225.6) 492.3 (354.1) 0.004
AUC0–24 in ELF (mg h/L) 101.5 (78.7) 175.9 (258.7) 0.047
Ratio AUCELF/AUCplasma (%) 31.8 (33.9) 36.4 (44.4) > 0.999
Fig. 4 Comparison of the individual predicted AUC48–72 h and the simulated AUC48–72 h in the plasma and ELF. Comparison of the individual
predicted AUC48–72 h using the Bayesian posterior estimated concentrations (red diamonds) and the simulated AUC48–72 h (black diamonds) in
the plasma and ELF with two different dosages of meropenem (2 g loading dose (LD) followed by 1 g/8 h as a continuous infusion (a) and 2 g
LD followed by 2 g/8 h as a continuous infusion (b))
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Several studies have identified the administration of
carbapenems as an independent risk factor for the
emergence of carbapenem-resistant Gram-negative
bacteria in ICU patients [41, 42]. In this scenario, one
proposed strategy to minimize the emergence of
resistance of meropenem is the administration to
achieve sufficient drug exposures to kill both suscep-
tible and prevent the emergence of resistant subpopu-
lations [43, 44]. Tam et al. reported that selective
amplification of subpopulations of P. aeruginosa with
reduced susceptibilities to meropenem was suppressed
with a Cmin/MIC of ≥ 6.2 in the plasma [43]. In fact,
some authors consider that no single agent can
achieve an adequate exposure to provide a cell kill
sufficient to allow optimal clinical outcomes and sim-
ultaneously suppress amplification of less susceptible
subpopulations of organisms in infections caused by
some bacteria, such as P. aeruginosa [44].
In pneumonia, a PK/PD target at the site of the infec-
tion of fT>MIC of 50% in ELF has been associated with
bacterial killing and suppression of resistant subpopula-
tion amplification in a murine model of pneumonia [14].
Unlike other PK/PD targets calculated in the plasma [45,
46], this has been more precisely defined at the site of
the infection. This was the pharmacodynamic target
used in this analysis and is higher than that often cited
for the efficacy of the carbapenem class.
Several studies have assessed the PK/PD of merope-
nem in ELF [10, 47–49], but only two of them have
focused on critically ill patients [10, 48]. Both studies
assessed ELF meropenem concentration and lung
penetration with the use of both intermittent and 3-h
extended infusion. Although a higher penetration ratio
(AUCELF/AUCplasma) of meropenem was observed with
the use of an extended infusion, none of the two
regimens achieved an optimal PK/PD target in ELF [48].
Fig. 5 Probability of target attainment (PTA) in ELF of different dosages regimens. PTA in ELF of different dosages of meropenem: 2 g loading
dose (LD) followed by 1 g/8 h, 2 g LD followed by 2 g/8 h, and 3 g LD followed by 3 g/8 h; administered as a continuous infusion during the third
day of treatment (from 48 to 72 h after the start of the treatment)
Fig. 6 Comparison of the time course of meropenem concentrations simulated in ELF. Comparison of the median, percentile 5th and 95th time
course of meropenem concentrations simulated in ELF during 4 days with different dosing regimens of meropenem as a continuous infusion (2 g
loading dose (LD) followed by 1 g/8 h (a), 2 g LD followed by 2 g/8 h (b), and 3 g LD followed by 3 g/8 h (c))
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To our knowledge, this is the first population PK study
of meropenem in critically ill patients with nosocomial
pneumonia which compared two different dosages ad-
ministered as a CI. Our results showed that the adminis-
tration of 2 g/8 h of meropenem as a CI allowed to
achieve higher meropenem concentrations in the plasma
and ELF compared to the 1 g/8 h dose, although a high
interindividual variability in the meropenem concentra-
tions in ELF was observed. However, even the adminis-
tration of the highest licensed dose (2 g/8 h) of
meropenem by CI in patients with conserved renal func-
tion did not result in an optimal ELF target attainment
for a substantial fraction of the population.
The median penetration ratio into the lungs was
approximately 30% and was comparable between both
groups. Similar penetration ratios (AUCELF/AUCplasma)
have been reported in other contexts [10, 14, 48].
Lodise et al. simulated a penetration of 26% in
patients with VAP after the administration of a single
dose of 2 g meropenem given over 3 h [10], and the
authors also reported a substantial variability in the
lung penetration ratio (10th and 90th percentiles of
3.7% and 178.0%, respectively). In the same way, the
PROMESSE study performed in 55 critically ill
patients with severe pneumonia treated with 1 g/8 h
reported a statistically higher AUC penetration ratio
in the extended infusion group (3 h) compared to the
intermittent group [mean (SD) 29 (± 3) % vs 20 (± 3) %
(P = 0.047)] [48]. In our study, all ELF samples were
obtained at the same time; hence, a precise estimate
of the concentration-time profile of meropenem in ELF
was not possible.
In our study, AUC in ELF was positively correlated
with AUC in the plasma, suggesting that plasma expo-
sures are a potential surrogate marker of lung exposures.
However, the correlation was not especially strong, and
plasma concentrations cannot be used to confidently
predict lung concentrations. Although we acknowledge
that routine measurement of drug levels in ELF is infeas-
ible in all critically ill patients with pneumonia, direct
lung measurement in those patients at risk of treatment
failure (especially if pathogens with high MIC values are
suspected) may be reasonable and should be considered.
In our study, a higher proportion of patients with clin-
ical cure achieved an optimal PK/PD ratio at the infec-
tion site compared to those who failed. Although our
findings suggest an association between the achievement
of an optimal PK/PD of meropenem in lungs and better
clinical outcomes in patients with Gram-negative
respiratory infections, this was not an objective in our
study. In addition, all patients received concomitant
treatment with nebulized CMS, which could have
influenced patients’ clinical outcomes, especially on
microbiological eradication. Due to all these reasons, our
results have to be confirmed in a larger prospective
clinical study.
Our work is the first study assessing the achievement
of a PK/PD target at the site of infection with the use of
different dosages of meropenem administered by CI.
Our results suggest that an optimal PTA can be achieved
Fig. 7 Visual predictive check plot for meropenem concentrations. Visual predictive check plot for meropenem concentrations at a dose of 2 g
loading dose + 1 g/8 h (a) and at a dose of 2 g loading dose + 2 g/8 h (b) in the plasma and ELF (left and right, respectively). Observed
concentrations (blue circles); simulated concentrations at the designated quantile given by the number on the line (lines)
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for MIC values < 2mg/L with a dose of 1 g/8 h and for
MIC values < 4 mg/L with a higher dose of 2 g/8 h. A
lower coverage (a lower MIC dilution) was reported with
the use of the same doses of meropenem administered
by extended infusion (over 3 h) in the PROMESSE study.
The authors used a similar target, 54% fT>MIC in ELF, a
value associated with microbiological response in a clin-
ical study of Li et al. [50], and observed that an optimal
PTA could only be attained for MIC breakpoints of 0.5
mg/L and 1mg/L with meropenem doses of 1 g/8 h and
2 g/8 h, respectively, administered by extended infusion
(3 h). Similarly, Drusano et al. confirmed that even with
the highest licensed meropenem dose, the 50% fT>MIC
in ELF target could not be achieved even at very low
MIC values (0.25 mg/L) [14]. Although the administra-
tion of meropenem by CI seems to improve drug expo-
sure in ELF compared with extended infusion [48], it
might not be sufficient to cover all intermediate Gram-
negative pathogens causing nosocomial pneumonia in
critically ill patients with conserved renal function. In
those cases, alternative strategies may be required, espe-
cially when pathogens with high MIC values (> 2 mg/L)
may be present. In fact, we estimate the meropenem
dose by CI needed to achieve an optimal PTA for all
considered intermediate strains (MIC between 2 and
8mg/L) [23] that would have to be as high as 8 g/8 h, a
dose that is four times higher than the highest approved
meropenem dose, and that is related to a high probability
of toxicity.
Our study has several limitations. Firstly, it is a relatively
small single-center study. Secondly, all ELF measurements
were performed at a single time point. The collection of
ELF samples at different times would have allowed a more
precise determination of the concentration-time profile in
ELF. However, a recent study demonstrated that ELF
models constructed with concentrations from sparse ELF
sampling time points result in exposure estimates similar
to those constructed from robustly sampled ELF profiles
[51]. Thirdly, all samples were collected on the same day,
so intraindividual variability during the treatment period
could not be measured [52]. ELF samples were all col-
lected in the infected lung; as distribution of inflammation
is heterogeneous, the collection of samples in the clear
lung could have led us to know the differences in the anti-
biotic diffusion. Finally, the relatively limited sample size
and the use of combination therapy with nebulized CMS
made difficult to correlate the PK/PD target in ELF with
clinical and microbiological outcomes. Nevertheless, this
study provides important and useful information about
the meropenem dosages that should be used in clinical
practice for treating nosocomial pneumonia caused by
Gram-negative bacteria in critically ill patients, consider-
ing both the achievement of clinical cure and possibly the
prevention of the emergence of resistance.
Conclusions
In conclusion, the administration of meropenem by con-
tinuous infusion improves drug exposure in the ELF, but
the use of the highest licensed dose (2 g/8 h) is still
needed to achieve a target attainment in ELF of > 90%
for isolates with an MIC up to 2 mg/L in patients with
conserved renal function. Alternative therapeutic stra-
tegies may be required for the treatment of nosocomial
pneumonia caused by Gram-negative bacteria in criti-
cally ill patients when MDR strains with high MIC values
are suspected.
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